Document Detail


Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
MedLine Citation:
PMID:  17762337     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Both erlotinib (E) and bortezomib (B) have shown single-agent activity in patients with non-small cell lung cancer. We studied the combination of these two novel biologic agents in vitro using a panel of non-small cell lung cancer cell lines.
METHODS: The growth inhibitory effect of E and B were determined by MTT assay on seven non-small cell lung cancer cell lines. The data obtained from the growth inhibition assay in response to the combination of E and B were subject to isobologram analysis. The effects of each individual drug as well as combination in different sequences on cell cycle and apoptosis were determined by flow cytometry.
RESULTS: Two of seven cell lines are sensitive to E. However, B has narrower range of cytotoxicity. The combination is neither synergistic nor additive in two of four cell lines tested. In H358 bronchoalveolar cell lines, the combination is more active than either agent alone. E causes G1 cell cycle arrest and B causes G2/M cell cycle arrest. In sequential studies, 24-hour previous exposure to E causes G1 arrest and abrogates the cytotoxic effect of B. This is observed in both E-sensitive as well as E-resistant cells and is accompanied by an increase in cell survival and a decrease in apoptosis.
CONCLUSIONS: The combination of E and B is neither additive nor synergistic in two of four cell lines tested. In H358 bronchoalveolar cell, the combination is more active than either agent alone. The schedule-dependent antagonistic effect of E pre-exposure was observed. E pre-exposure causes G1 cell cycle arrest and abrogates the activity of B. Further in vivo studies of this combination are warranted.
Authors:
Bilal Piperdi; Yi-He Ling; Roman Perez-Soler
Related Documents :
2425987 - The interaction with pdgf as a source of g1 phase heterogeneity in normal mouse fibrobl...
12388347 - Activation of the g2 cell cycle checkpoint enhances survival of epithelial cells expose...
2382977 - Cell kinetics (samba 200) of estradiol stimulated long-term phenol red withdrawn cultur...
7019917 - Nature of the g1 phase of the yeast saccharomyces cerevisiae.
17227437 - Down-regulation of dopamine transporter by iron chelation in vitro is mediated by alter...
16893667 - Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant hum...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer     Volume:  2     ISSN:  1556-1380     ISO Abbreviation:  J Thorac Oncol     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-08-31     Completed Date:  2007-10-11     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101274235     Medline TA:  J Thorac Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  715-21     Citation Subset:  IM    
Affiliation:
Division of Medical Oncology, Department of Medicine, UMass Memorial Cancer Center, University of Massachusetts, Worcester, Massachusetts 01655, USA. piperdib@ummhc.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Apoptosis
Boronic Acids / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*,  pathology
Cell Cycle
Cell Proliferation
Drug Interactions
Drug Therapy, Combination
Humans
Lung Neoplasms / drug therapy*,  pathology
Protease Inhibitors / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Pyrazines / therapeutic use*
Quinazolines / therapeutic use*
Receptor, Epidermal Growth Factor / antagonists & inhibitors*,  metabolism
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Boronic Acids; 0/Protease Inhibitors; 0/Protein Kinase Inhibitors; 0/Pyrazines; 0/Quinazolines; 0/bortezomib; EC 2.7.10.1/Receptor, Epidermal Growth Factor; J4T82NDH7E/erlotinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the ...
Next Document:  Differences in primary care clinicians' approach to non-small cell lung cancer patients compared wit...